Skip to Content

Deflazacort Dosage

Applies to the following strengths: 6 mg; 18 mg; 30 mg; 36 mg; 22.75 mg/mL

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Muscular Dystrophy

0.9 mg/kg orally once a day

Comments:
-If tablets are used, round up to the nearest possible dose
-If oral suspension is used, round up to the nearest tenth of a milliliter (mL).
-If this drug is administered for more than a few days, do not abruptly discontinue.
-Dose modifications are recommended for use with CYP450 3A4 inhibitors and inducers (see dose adjustments).

Use: Treatment of Duchenne muscular dystrophy.

Usual Pediatric Dose for Muscular Dystrophy

5 years or older: 0.9 mg/kg orally once a day

Comments:
-If tablets are used, round up to the nearest possible dose
-If oral suspension is used, round up to the nearest tenth of a milliliter (mL).
-If this drug is administered for more than a few days, do not abruptly discontinue.
-Dose modifications are recommended for use with CYP450 3A4 inhibitors and inducers (see dose adjustments).

Use: Treatment of Duchenne muscular dystrophy.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

Mild or moderate impairment: No adjustment recommended
Severe impairment: Data not available; no dosing recommendation can be provided

Dose Adjustments

Moderate or Strong CYP450 3A4 Inhibitors: Give one-third of the recommended dosage

Moderate or Strong CYP450 3A4 Inducers: Avoid use

Do not take with grapefruit juice

Precautions

Safety and efficacy have not been established in patients younger than 5 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Take with or without food
-Do not take with grapefruit juice

-Tablets: May be taken whole or crushed; if crushed, may mix with applesauce and take immediately after mixing

-Oral suspension:
-Shake well before measuring dose; use provided measuring device to ensure accurate dosing
-Slowly add measured dose into 3 or 4 ounces of juice or milk and mix well; administer immediately
-Wash dispenser after each use

Storage requirements:
Oral Suspension:
-Store upright at room temperature; discard 1 month after first opening

General:
-Do not stop therapy abruptly; gradually reduce dose if the drug has been administered for more than a few days.
-In clinical trials, patients receiving 1.2 mg/kg/day demonstrated small additional benefits but had a greater incidence of adverse reactions; the use of this dose is not recommended.
-This corticosteroid is derived from prednisolone; deflazacort 6 mg has approximately the same antiinflammatory potency as 5 mg of prednisone or prednisolone.

Monitoring:
-Monitor growth velocity and development in pediatric patients
-Monitor intraocular pressure if therapy is continued for more than 6 weeks; regular eye exams should be encouraged
-Routine laboratory studies (including 2-hour postprandial blood glucose and serum potassium), blood pressure, weight, bone mineral density, and chest x-rays should be performed at regular intervals for patients on long-term corticosteroid therapy
-Monitor for hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and hyperglycemia with chronic steroid users

Patient advice:
-Patients should understand that this drug should not be stopped abruptly or without medical advice; additionally, all healthcare professionals providing care should be informed of current and past corticosteroid use.
-Patients should understand that during times of stress, such as surgery or infection, additional supplementation doses may be necessary; they should discuss with their healthcare professional whether they need to carry a medical identification card that identifies their corticosteroid use.
-Patients on immunosuppressant doses of corticosteroids should understand that a greater risk of infection exists; they should avoid exposure to chickenpox or measles and if exposed, they should consult their healthcare professional promptly.
-Patients should check with their healthcare provider before receiving any vaccinations.
-Patients should be advised of common adverse reactions including changes in glucose tolerance, high blood pressure, behavioral/mood changes, increased appetite, and weight gain.
-Patients should understand the risks of prolonged use including decreased bone mineral density and ophthalmic effects and that regular monitoring is necessary.

Hide